Gain Therapeutics (GANX) vs Lifevantage (LFVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Lifevantage (LFVN) over the past year, losing 22.0% versus a loss of 34.9%. Over five years, LFVN leads with a -12.2% price change compared with -76.7% for GANX. Lifevantage is the larger company by market cap ($75.4 million vs $70.5 million), about 1.1 times the size.
Lifevantage pays a dividend yielding 3.09%, while Gain Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | LFVN |
|---|---|---|
| Share price | $1.62 | $5.99 |
| Market cap | $70.48M | $75.41M |
| 1-day change | -3.29% | -0.17% |
| YTD return | -49.84% | -2.76% |
| 1-year return | -21.98% | -34.89% |
| 5-year return | -76.73% | -12.17% |
| P/E ratio (TTM) | — | 14.97 |
| Forward P/E | — | 15.49 |
| EPS (TTM) | $-0.50 | $0.40 |
| Dividend yield | 0.00% | 3.09% |
| Annual dividend | $0.00 | $0.185 |
| 52-week high | $4.34 | $11.71 |
| 52-week low | $1.53 | $3.90 |
| Distance from 52-week high | -62.79% | -48.85% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +345.82% | +25.21% |
| Average volume | 493.98K | 59.73K |
| Shares outstanding | 43.64M | 12.59M |
| Employees | 20 | 209 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed LFVN by 12.9 percentage points over the past year.
- Lifevantage offers a meaningfully higher dividend yield (3.09% vs 0.00%).
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Lifevantage
LFVN stock →LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Health Care · Biotechnology: Pharmaceutical Preparations · 209 employees
GANX vs LFVN FAQ
Which is bigger, Gain Therapeutics or Lifevantage?
Lifevantage (LFVN) is larger, with a market capitalization of $75.41M compared with $70.48M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or LFVN?
GANX returned -21.98% over the past 12 months, compared with -34.89% for LFVN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gain Therapeutics or Lifevantage?
Lifevantage pays a dividend yielding 3.09%, while Gain Therapeutics does not currently pay a regular dividend.
Are Gain Therapeutics and Lifevantage in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.